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ABSTRACT
Objective: Peptic ulcer is a disease caused due to an imbalance of aggressive and defensive factors in the body. Helicobacter pylori infections and 
colonization are also associated strongly to the peptic ulcer disease. Bismuth-containing organic compounds have been attributed to a major influential 
role in the successful treatment of peptic ulcer by inhibiting gastric acid secretion and provide cytoprotective properties which result in ulcer healing. 
Hence, the objective of this review is to discuss recent approaches and future perspectives of organobismuth compounds in the treatment of peptic 
ulcer.
Results: A total of 112 papers were included in the review, among them 20 papers describe the pathophysiology of peptic ulcer, 10 papers discuss 
about diagnostic test for H pylori infection, 4 papers describe the drug regimen used in peptic ulcer treatment, 13 papers discuss about failure and 
alternative therapies for treatment of peptic ulcer, 8 papers describe the chemistry of bismuth, 20 papers discuss about mechanism of action of 
bismuth, 27 papers describe the newer bismuth complexes for H. pylori eradication, and 8 paper discuss about gastroprotective activity of bismuth-
containing derivatives.
Conclusion: Organobismuth compounds/drugs are effective to eradicate H. pylori in conjunction with antibiotics. It also provides gastroprotective 
action and dramatic decrease of relapse rate which accounts for further exploration of organobismuth compounds to pave new ways for the design 
and synthesis of novel compounds in the effective treatment of peptic ulcer.
Keywords: Peptic ulcer, Helicobacter pylori, Organobismuth drugs, Eradication, Gastroprotective.
INTRODUCTION
The peptic ulcer disease (PUD) is mainly the development of gastric 
erosion or ulcers on various regions of the alimentary canal which 
occurs when there is an increase in acid and pepsin activity in gastric 
juice toward the mucosal barrier. It may be represented by a pseudo 
equation: PUD Imbalance between gastric acid secretion and mucosal 
defense mechanism 
Factors including genetic and non-genetic are involved [1] which 
results in imbalance of aggressive factors (such as acid, pepsin, 
refluxed bile, leukotriene, and reactive oxygen species [ROS]) and 
defensive factors (mucus secretion and thickness, bicarbonate, mucosal 
prostaglandins, mucosal blood flow, mucosal repair and restitution, 
non-enzymatic and enzymatic antioxidants, and some other growth 
factors) [2,3] Nonsteroidal anti-inflammatory drugs (NSAIDs) and low-
dose aspirin are also an increasingly important cause of ulcers and their 
complications [4,5]. Helicobacter pylori infections and colonization 
are also associated very strongly to the PUD [6] which results in an 
imbalance of aggressive and defensive factors. Hence, peptic ulcers can 
be classified as:
a) Ulcers due to hypersecretion of acid (Zollinger-Ellison syndrome).
b) Ulcers due to NSAIDs.
c) Ulcers which are integrated with H. pylori infection [7].
Risk factors from the environment [8], may increase the erosion to 
mucosal wall, include excessive drinking of alcohol [9], smoking [10,11] 
or chewing tobacco, emotional stress, and psychosocial factors [12,13]. 
Complications of PUD are hemorrhage, bleeding, perforation, and 
gastric outlet obstruction [14].
H. PYLORI – A CENTRAL PATHOGENIC FACTOR IN PEPTIC ULCER
Acid and pepsin are important factors in causing the erosion along with 
infections due to H. pylori, which is important as central pathogenic 
mechanism of ulcerogenesis, weakening the gastro duodenal defenses 
and altering somatostatin, gastrin and acid homeostasis [15]. H. pylori 
infects about 50% of the world’s population due to adaptations thereby 
preventing detection by the immune system. It is a spiral to coccoid-
like-shaped Gram-negative bacterium, having flagella which make it 
motile in viscous mucus in the stomach. It binds on epithelial gastric 
cells and causes a release of proteins from the outer membrane and also 
an expression of urease, catalase, and oxidase enabling the organism 
to survive in an acidic stomach environment. Acquisition of bacterium 
in humans occurs in childhood, the infection rate for either sex is 
similar [16] and if untreated then infection is lifelong [17]. The infection 
is mainly transmitted through the fecal–oral route in developing 
countries and gastro-oral route in developed countries [18]. Over 90% 
and 70% of duodenal ulcer (DU) and gastric ulcer (GU), respectively, 
are related to infection through H. pylori [19]. Fig. 1 explains the 
pathogenesis of peptic ulcer by the acquisition of H. pylori and other 
factors. H. pylori strains phenotypically can be divided into two groups; 
Type 1 contains vacuolating toxin, encoded by the gene vacA (94-kda 
vacA) and cytotoxin-associated protein encoded by the gene cagA 
(120-128-kcagA) and Type 2 contains non-cytotoxic vacA and cagA 
negative strains. It has been observed that Type 1 strains cause more 
intensive inflammation than Type-2 [20].
ERADICATION THERAPY
H. pylori eradication is the least expensive approach for curing 
ulcer disease [29] and also helps for the healing of both DU and GU. 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i5.32679
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Eradication also results in a dramatic decrease of relapse rate and 
maintain protein concentration in the stomach to normal. It also 
eliminates the need for maintenance therapy [30]. H. pylori infection 
is associated with gastric carcinogenesis and eradication can reduce 
the lifetime risk of gastric cancer. Tables 1 and 2 provides details of 
diagnostic test and drug regimen for H. pylori and Fig. 2 details about 
the structures of these reported drugs for eradication of H. pylori. 
Recommendation of H. pylori eradication is given for those patients 
who were suffering from PUD, gastric mucosa-associated lymphoid 
tissue lymphoma, atrophic gastritis, after gastric cancer resection, 
first-degree relative patients of gastric cancer, investigated non-ulcer 
dyspepsia, users of NSAIDs, unexplained iron deficiency anemia, 
etc. A different regimen of drugs including different categories 
of antibiotics, proton pump inhibitors (PPI), and bismuth-based 
drugs [31] are available for the eradication of H. pylori.
Fig. 1: Pathogenesis of peptic ulcer
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The main reasons for eradication failure of H. pylori infection include 
antibiotic resistance, poor compliance, and rapid metabolism of PPI.
FAILURE IN ERADICATION THERAPY
The eradication therapy H. pylori is failed due to major reasons such 
as (a) rapid metabolism of PPI and (b) antibiotic resistance with the 
most commonly used antibiotic, clarithromycin. The resistance is 
unevenly distributed worldwide, resistance rates being higher in 
developed countries than in developing countries. A quinolone often 
used is levofloxacin for which resistance is also a concern. Development 
of resistance to these two important antibiotics can decrease the 
standard level of eradication from 90% to less. Other antibiotics used 
include metronidazole, amoxicillin, tetracycline, and rifampicin. Larger 
consumption of these antibiotics may also develop resistance resulting 
in decreased eradication rates (c) side effects of drugs leads to decreased 
patient compliance and (d) H. pylori can assume a resting coccoid 
form which is not susceptible to antibiotic treatment. The bacterium 
may remain inside the epithelial cell or in the stomach mucus layer 
limiting drug access. Hence, finding an alternative drug therapy which 
overcomes these problems is necessary. Various alternatives such as 
plant material [32], probiotics [33], peptides [34], polysaccharides [35], 
microorganisms, vaccines [36], and many more are explored. In this 
context, organobismuth drugs put forth an important role through a 
different mechanism of action like binding to proteins and enzymes 
interacting networks which provide prevention of H. pylori-associated 
diseases. Hence, it is required to explore more about organobismuth 
drugs which improve its solubility as well as pharmacokinetic and 
pharmacodynamic properties such that they are more effective. Table  3 
provide details of enzymatic targets for organobismuth compounds.
ALTERNATIVE THERAPIES OF ORGANOBISMUTH COMPOUNDS
Bismuth-containing triple or quadruple therapy is an alternative line of 
the treatment for H. pylori infection [37,38] because these are safe and 
exert local effects [39] and resistance to bismuth drugs has not been 
reported yet [40] for H. pylori or any other pathogenic microorganism. 
Bismuth can act as an antimicrobial agent toward H. pylori by suppressing 
them but do not eliminate it but when administered with antibiotics 
provide synergistic effects to the antibiotics. Hence, use of these drugs 
may also reduce the resistance risk of other coadministered antibiotics 
such as clarithromycin and metronidazole and slow down the relapse 
rate of H. pylori infection. Numerous different bismuth-based compounds 
are available, such as colloidal bismuth subcitrate [41] (colloidal bismuth 
subcitrate [CBS] used for dyspepsia, DU, and GU), bismuth subsalicylate 
(BSS used for traveler’s diarrhea, dyspepsia, and H. pylori), bismuth-
subnitrate (for gastric disorders, constipation, and irritable colon), and 
the newer ranitidine bismuth citrate [42,43] (RBC-for H. pylori, DU, and 
GU). In addition, many bismuth nanotubes of novel bismuth compounds 
having different structures have been synthesized and are active toward 
the eradication of H. pylori by exerting different MOA. Its application in 
colloidal form and low dosage (below 0.5 g/day) reduces toxic side effects 
by reducing its absorption which excludes potential neurotoxicity [44]. In 
serum bismuth forms strong complexes with lactoferrin and transferrin 
and this phenomenon also play an important role for low toxicity [45]. 
Bismuth-containing medicaments are available in the form of colloidal 
suspensions, ointments, injectables, liquids, solves, and tablets.
CHEMISTRY OF BISMUTH
Bismuth is an element of Group 15 located in the bottom of the periodic 
table having an atomic number of 83 and atomic mass of 209 which 
is the only naturally occurring stable isotope. Bismuth is a soft, silvery 
metal with a bright surface and density of 9.78 g/cm3. Although 
bismuth occurs naturally in earth crust in small quantities as a pure 
form, its crustal abundance is very low that is 8ppb as it is reported as 
a 69th abundant element and is less common than indium, cadmium, 
and only twice as common as gold [46]. The electronic configuration 
of [Xe] 4f145d106s26p3 allowing bismuth to accept an electron pair 
readily as well as the availability of unoccupied orbitals elevates its 
affinity to extend coordination. Two main oxidation states are found in 
nature (+3 example bismuth halides, BSS, etc., and +5 example bismuth 
(V) fluoride). It also found in the ore form in bismuthinite [47], bismuth 
glance (Bi2S3), bismuth ocher (Bi2O3), and bismutite [(BiO)2CO3·H2O] 
[48]. It is also found as a by-product in refining lead, copper [49], tin, 
silver, and gold. The metal exists in three allotropic forms, but the only 
rhombohedral form is stable. Its melting point is 271°C and its boiling 
point is 1560°C [50]. Bismuth in the oxidation state of +3 behaves 
like a Lewis acid when bonded to an electronegative atom and thus 
is used as an important catalyst for various industrial applications. 
Due to the Lewis acidic nature of the bismuth (III) center, additional 
intra- and inter-molecular bonds can develop and thereby result in 
extended coordination structures (coordination number is 3–10), for 
example, bismuth nitrate pentahydrate, [Bi(NO3)3.5H2O] exhibits a ten 
coordinate geometry around the bismuth (III) center. Compounds of 
bismuth (IV) [51] may exist and the solid state compounds of bismuth 
(V) – alkali metal bismuthates are also known. The ions of bismuth (V) 
do not exist in solution [52]. The bismuth (I) complex in the solution is 
available by dissolving metallic Bi in conc. hydrochloric acid; however, 
this solution is reported to be unstable [53]. In three coordinate triaryl 
and alkyl bismuth (III) compounds, the Bi (III) center obeys the octet 
rule resulting in a trigonal pyramidal coordination geometry, which is 
in agreement with the valence shell electron pair repulsion theory.
Bismuth-containing quadruple therapy is an alternative line of 
treatment for H. pylori infection recommend-ed.
REPORTED MECHANISMS OF BISMUTH ACTION
Bismuth disrupts multiple biological pathways of H. pylori such as 
tricarboxylic acid cycle, cell redox homeostasis, nickel homeostasis, 
protein folding, and iron homeostasis [54]. The MOA of bismuth 
against H. pylori have been reviewed and it is assumed that it may 
produce antimicrobial action by different complex mechanisms such as 
obstructions in the biological activity of enzymes produced by H. pylori, 
for example, urease, alcohol dehydrogenase (ADH), fumarate reductase, 
fumarase, and proteases (pepsin and phospholipase C and A2) [55,56]. 
It affects the climate of the organism for its growth and hindrance 
of the union of H. pylori to surface epithelial cells [57]. Bismuth also 
exerts its mechanism by impediment of adenosine triphosphate 
adenosine triphosphate synthesis [58], retardation of protein, cell wall 
synthesis, and membrane function [59] through complex formation 
and a depletion in capsular polysaccharide production [60]. On the 
other side, it is also assumed that it inhibits gastric acid secretion [61] 
and provides cytoprotective [62] like properties which result in ulcer 
healing.
Bi present in organobismuth compounds can bind to intracellular 
proteins of H. pylori such as HspA, HspB, and NapA, it binds to heat 
shock protein-A (HspA) protein of the bacterium and disrupts nickel 
homeostasis, is reported by metalloproteomic approach. HspA protein in 
the organism is essential for urease activation and urease is responsible 
for its survival in an acidic environment. Bismuth can binds to nickel 
in the histidine (His-) and cysteine Cys-rich metal binding domain at C 
terminus [67]. Iron metabolism pathway of H. pylori is also disrupted 
by Bi and was demonstrated through metallomics approach. Bismuth 
binds to ferric uptake regulator (fur) protein at S1 site, which increases 
protein oligomerization and there is loss of DNA binding power. It 
reduces transcriptions in regulated genes, which are pivotal for bacterial 
physiology [68,69]. Disruption of iron equanimity can also result in the 
production of ROS which produces oxidative stress in the bacterium 
leads to injury in DNA and membrane [70]. Membrane damage leads to 
bacterial autolysis. It upregulates the expression of protein thioredoxin 
which also leads to a high level of oxidative stress to the organism.
Bismuth complexes with thiolate
Bismuth (III) compounds binds strongly with thiolate sulfur, bismuth 
forms a coordinate bond with thiolate group of amino acid cysteine 
is predicted through infrared (IR) spectroscopy. Its simultaneous oral 
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administration produces a remarkable rise in blood plasma bismuth. 
The complex [(SC(CH3)2CH(NH2)CO2] BiCl shows that chelation by 
sulfur, nitrogen, and oxygen of tridentate D-penicillamine reported 
through X-ray crystallography [71] bismuth also forms well-constructed 
complexes with the tripeptide glutathione and N-acetyl-L-cysteine. 
Glutathione plays a crucial role in the transportation and distribution 
of bismuth (III) in cells and bio-fluids. As it is widely used for binding 
of Bi by hugepeptides and proteins. Each Bismuth (III) ion results in 
the cotransport of three molecules of glutathione. 1H-nuclear magnetic 
resonance (NMR) studies reveal that Bi appears to pass slowly through 
cell membranes by a shuttle mechanism involving membrane proteins 
and forms an intracellular complex with glutathione (gsh) possibly 
[Bi(H-1gsh)3].
Bismuth complexes with metallothionein
Cell differentiation and proliferation are controlled by metallothionein 
protein. It helps to detoxicate metallic ions such as Cd (II), Hg (II), 
and Au (I), helps to subscribe Zn (II) to apo-enzymes, play a role in 
neurophysiology, and is a target for Bi (III) in the brain. The structure of 
metallothionein composed of two domains-α and β having two metal-
thiolate clusters. Structures are predicted using X-ray crystallography 
and NMR by Shaw and Savas [72]. The α-domain (C-terminal) contains 
11 cysteine and forms a cluster of 4 Cd or Zn ions bound to 5 bridging 
and 6 terminal cysteine thiolates. The β-domain (N-terminal) contains 
9 cysteine and forms a cluster of 3 Cd or Zn ions which is ligand by 3 
bridging and 6 terminal cysteine thiolates. It is well known that bismuth, 
when administered with cisplatin can reduce the side effects because 
bismuth (III) is a potential inducer of metallothionein synthesis in 
the kidney. The strong affinity of bismuth to metallothionein in a ratio 
of 7:1 is due to bismuth higher affinity for thiolate ligands which are 
present in metallothionein.
Bismuth binding to transferrin and lactoferrin
Bismuth (III) binds relatively strongly to transferrin due to its high 
acidity. Transferrin is a glycoprotein which helps in transportation of 
iron in the blood. Lactoferrin is a similar kind of protein to transferrin 
and found in the mucus of human. Transferrin is only 30% bound to 
iron in blood so it can bind to other metals such as bi (III), Ga (III), and 
Table 1: Diagnostic test for H. pylori infection
Test division Test name Test description Reference
Test with endoscopy RUT pH of the biopsy specimen is measured (if alkaline shows the presence) [21]
Bacterial culture Determination of antibiotic sensitivities by the development of culture of the 
microorganism
[22]
Histology Provide auxiliary information on degree and pattern of inflammation [23]
FISH Localization and identification of H. pylori [24]
Molecular approach: PCR Very sensitive and less time consuming (DNA probe technology) [25]
Test without endoscopy SAT Examination of the stool to check the presence of H. pylori [26]
Finger-stick serology test H. pylori-specific IgG antibodies presence is checked
Whole blood serology H. pylori-specific IgG antibodies presence is checked [27]
13C-urea breath test Urea metabolism principle is used for H. pylori eradication analysis [28]
14C-urea breath test Urea metabolism principle is used for H. pylori eradication analysis
RUT: Rapid urease test, FISH: Fluorescence in situ hybridization, PCR: Polymerase chain reaction, SAT: Stool antigen test, H. pylori: Helicobacter pylori
Table 2: Drug regimen for H. pylori eradication 
S. No. Therapy Drug category Drug example
1. Monotherapy Antibiotics, H2RA, or Bismuth compounds Clarithromycin (2), ranitidine (4), famotidine (5), nizatidine (6) or 
CBS (11), RBC
2. Dual therapy Two antibiotics, PPI+antibiotics or 
Bismuth+antibiotics
Omeprazole (1), levofloxacin (7) and amoxicillin (8), or 
omeprazole, amoxicillin, and rifabutin CBS+metronidazole
3. Triple therapy Bismuth+antibiotics+PPI, H2RA+2 antibiotics CBS+amoxicillin+omeprazole, 
Ranitidine+metronidazole (3)+amoxycillin
4. Quadruple therapy PPI+Bismuth+two antibiotics Omeprazole+CBS or BSS (12)+tetracycline (9)+ tinidazole (10)
H. pylori: Helicobacter pylori, PPI: Proton pump inhibitor, CBS: Colloidal bismuth subcitrate, BSS: Bismuth subsalicylate, RBC: Ranitidine bismuth citrate
Table 3: Enzymatic targets for organobismuth compounds
S. No. Enzyme Enzyme activity Inhibitory activity by bismuth drug Type of inhibition Reference
1. Urease Neutralization of the gastric acid by 
hydrolyzing urea to ammonia
Blocking the substrates from reaching the 
active site by binding to cysteine (Cys319) 






Catalyzes reversible oxidation of 
alcohol to acetaldehyde which 
arbitrates mucosal damage
Change in enzyme native structures by 
binding to a cysteine residue of Baker’s 




Essential for H. pylori colonization 
unidirectional conversion of fumarate 
to succinate
Binding of bismuth to the enzyme can 
inhibit the colonization of H. pylori
4. Fumarase Conversion of fumarate to malic acid 
for cellular energetics and production 
of ATP
Modification in bacterial flagellar rotation, 
disarrange 
bacterial energetics, obstruct the oxidative 
ATP composition
non-competitive [66]
5. Proteases Glycoprotein constituents of mucin 
are disgrace by phospholipase
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Al (III) and helps them to enter in human blood. Both N- and C-lobe 
iron-binding sites of human serum transferrin and recombinant 
N-lobe transferrin are vigorously binds to bismuth [73]. Similar to 
iron bismuth binds to transferrin along with carbonate as a synergistic 
anion, predicted by 13C-NMR. Even after extensive dialysis, removal of 
bismuth from transferrin complex cannot take place.
NEWER ORGANOBISMUTH COMPOUNDS AGAINST H. PYLORI
Diemer et al. synthesize and report single-crystal structures of novel 
complexes of bismuth with thiosemicarbazones and dithiocarbazonic 
acid methyl ester derivatives as a ligand which are also active 
against H. pylori [74]. Thiosemicarbazones were chosen for complex 
formation with bismuth due to their potential antibacterial and 
antiviral activity against influenza viruses, against protozoa, 
and Plasmodium berghei in mice and also against some types of 
tumor [75-78]. Complexes of thiosemicarbazones with different 
metal such as nickel, copper, iron, and cobalt were also reported as 
active to produce different biological activity. At low concentrations, 
all the novel complexes of bismuth with thiosemicarbazones and 
dithiocarbazonic acid methyl ester derivatives can actively inhibit the 
bacterium causing peptic ulcer.
Dittes report some new bismuth (III) and bismuth (V) tropolanato 
complexes along with thiosemicarbazones and dithiocarbazonic acid 
methyl ester derivatives in a review. Fig.3 details about the structures 
reported. An agar dilution test method is used to test activity against H. 
pylori for both types of complexes, the standards taken were bismuth 
citrate, bismuth salicylate, and bismuth nitrate aluminate and it was 
reported that thiosemicarbazones complexes were more active than 
the tropolonato complexes [79].
The interest toward the synthesis of new bismuth complexes extended 
and demand of therapeutically more efficacious bismuth compounds 
for some supplementary eradicate H. pylori leads to the synthesis of 
novel Bi (III) complexes of fluoroquinolones (norfloxacin, ofloxacin, 
ciprofloxacin, sparfloxacin, lomefloxacin, pefloxacin, and gatifloxacin) 
by Shaikh et al. [80]. Fluoroquinolones were chosen for the complex 
formation because they are already known broad-spectrum 
antibiotics [81] and the complex formed is an uncharged molecule so 
it is absorbed well and its bioavailability is also high. An agar diffusion 
method is used for the determination of activity against H. pylori 
and all complexes were found to be active with minimum inhibitory 
concentration (MIC) values of 1–4 mg/L (1–4 µg/mL).
Bismuth complex of sulfosalicylate prepared and recrystallized from 
water – [PhBi(HSsal)H2O], [PhBi(HSsal)EtOH], and {[Bi(HSsal)(H2Ssal)
(H2O)3]2·2H2O} was synthesized in the same year by Andrews et al. 
Single crystal X-ray diffraction helps to reveal that the three complexes 
were polymeric in nature. The compounds were tested for the activity 
against H. pylori; it was reported that all three complexes show 
notable activity against the bacterium H. pylori of <6.25 mg/ml [82]. 
Andrews also provide invaluable insight in this regard and propose and 
synthesize various novel complexes of bismuth with NSAIDs having 
general formula [BiL3]n or [BiL3·(H2O)]n where L is an NSAID [83]. 
They previously develop and establish methods for the successful 
formation of bismuth carboxylates [84], and bismuth salicylates [85] 
Fig. 2: Reported structures of drugs in Helicobacter pylori eradication
177
Asian J Pharm Clin Res, Vol 12, Issue 5, 2019, 172-181
 Singh et al. 
and NSAIDs are also salicylates and carboxylates, so these were used to 
synthesize the complex. The synthetic scheme adopted was:
BiPh3+3LH [Bi(L)3]n+3PhH
Reaction can be done in the presence of a solvent (Toluene, Reflux for 
10–12 h) or the absence of solvent (1200°C for 4 h) and L is the different 
NSAIDs used such as ketoprofen, naproxen, ibuprofen, mefenamic acid, 
diflunisal, 5-chlorosalicylic acid, fenbufen, sulindac, tolfenamic acid, and 
flufenamic acid. Here also an agar dilution method was used to analyze 
the activity against H. pylori. All ten complexes show excellent in vitro 
activity with MIC values of ≥6.25 mg/mL. Andrews also concentrated 
in the development of another complex of bismuth which exhibited 
remarkable anti-H. pylori activity with saccharinate and thiosaccarinate 
reported structures are given in Fig. 4 [86]. Five new complexes were 
synthesized [Ph2Bi(sac)]∞, [Bi(sac)3]n, [Ph2Bi(tsac)]∞, [PhBi(tsac)2]n, 
and [Bi(tsac)3]n. Metal complexes of Saccharinates were also reported 
earlier with metals such as zinc, copper, and cobalt; they give inhibitory 
effect on carbonic anhydrase [87,88]. Due to its chelation properties, 
it is used as an antidote for metal poisoning. The complexes were 
characterized by NMR, IR, and single- crystal X-ray diffraction and were 
tested against three strains of H. pylori B128, 251, and 26695. Agar 
dilution method was used to set the MIC values which was 6.25 μg/
mL for saccharin complex [Ph2Bi(sac)]∞, [Bi(sac)3]n and 50 μg/mL for 
[Ph2Bi-(tsac)]∞, 12.5 μg/mL for [PhBi(tsac)2]n, and 6.25 µg/mL for 
[Bi(tsac)3]n.
A range of bismuth (III) carboxylates were synthesized through salt 
metathesis using [BiPh3] and Ag(I), thallium(I) carboxylates. However, 
thallium is toxic and silver is expensive so they were replaced by 
Na and K [89] and the above methods were used to synthesize 
the bismuth (III) aminoarene sulfonate complexes with careful 
control of temperature and reaction conditions by Andrews et al. 
Aminoarenesulfonates were chosen due to their biological activities 
such as esterase and chymotrypsin-inhibitory, and hypolipidemic 
effect [90-92]. Numerous structural variations are available and their 
electronic property as well as structures are similar to amino acids. The 
position of the amino group on arene (-o, -p, -m), heterocyclic amines, 
monoprotic, and zwitterionic acids, and the ring size is varied from 
phenyl to naphthyl to choose the aminoarenesulfonates for complex 
development with bismuth. The yield of the synthesized complexes 
was compared and it was found that [Bi(OtBu)3] at a low temperature 
produces a high yield for homoleptic tris (aminoarenesulfonato) 
bismuth (III) complexes. However, heteroleptic bismuth (III) 
complexes are only accessible here through the use of the Ag (I) 
complexes in reaction with [Bi(Ph)3−n(Cl)n] (n=1 or 2). All complexes 
were powerful antimicrobials; active against H. pylori having MIC 
values ranged from 0.049 µg/mL to 12.5 µg/mL. The same group of 
scientist also proposes some newer bismuth (III) complexes derived 
from α amino acids. They describe various synthetic approaches 
using [BiPh3] [93] under both solvent-free and solvent-mediated 
methods; metathesis with Ag (I) [94] salts of the α-amino acids 
and with [Bi(OtBu)3] to synthesize tris-substituted bismuth (III) 
complexes using different polar and non-polar amino-acids such as 
L-phenylalanine, L-proline, L-methionine, L-cysteine, D,L-serine, 
L-tyrosine, L-aspartic acid, and L-glutamic acid [95] the first two 
methods were not feasible to synthesize the carboxylate complexes 
but the third method is superior using [Bi(OtBu)3] at low temperature. 
The amino acids were chosen for the formation of complexes because 
it was demonstrated earlier through different studies that bismuth 
acts in vivo on proteins and peptides containing sulfur in the form of 
thiolates [96] such as cysteine and methionine including lactoferrin 
and transferrin [97-99]. The reaction scheme using [Bi(OtBu)3] was:
3LHn+ m[Bi(OtBu)3] [BimL3]
The reaction is performed in the presence of THF, N2 at temperature 
−780°C–−400°C in Step 1 and −400C to RT in Step 2. For n=1, m=1 
and For n=2, m=2. Synthesized compounds were quick to respond to 
temperature and moisture and were characterized through elemental 
analysis, NMR, ATR-IR, and electrospray ionization mass spectrometry. 
The complexes were also tested for their reliability to active against 
H. pylori; MIC values ranged from 0.049 µg/mL to 50 µg/mL. The general 
progression allowed to manifest that bismuth (III) complexes of polar, 
neutral and aliphatic α-amino acids gave lower MIC values compared to 
the bismuth (III) complexes of non-polar, acidic, and aromatic α-amino 
acids.
In eager for searching more antibiotics for H. pylori eradication Andrews 
et al. also propose to synthesize bismuth (III) β-thioxoketonates. Nine 
different β-thioxoketonates of general formula R1C(=O)CH2C(=S)R2 
(R1 and R2=C6H5; R1=C6H5, R2=p-CF3C6H4; R1=p-MeOC6H4, R2=C6H5; 
R1=p-MeOC6H4, R2=p-CF3C6H4; R1=C5H4N, R2=C6H5; R1=p-IC6H4, 
R2=C6H5; R1=C6H5, R2=p-IC6H4; R1=C6H5, R2=C10H7, and R1=CH3, R2=C6H5 
and their tris-substituted bismuth (III) complexes were synthesized 
and well characterized by IR, NMR, and X-ray crystallography. All the 
bismuth (III) complexes were highly diligent against H. pylori with MIC 
values ≥3.125 µg/mL. The bismuth (III) β-thioxoketonates complexes 
were also tested for anti-leishmanial activity, but the only compound 
[Bi{C5H4NC(=O)CHC(=S)C6H5}3] showed the highest activity [100].
Interest toward the synthesis of complexes was increases and Andrews 
et al. recently synthesize the bismuth complex with hydroxamic acid. 
According to them, these were better candidates for complex build 
out because they also play a role in the inhibition of urease enzyme. 
Targeting bismuth
hydroxamates provide prospective to develop new antibacterial 
compounds and provide a plan of action using siderophores as “trojan 
horses” for the uptake of bismuth into the microorganism. H. pylori 
utilizes host transferrin, lactoferrin, and heme for iron uptake, so they 
provide a strong bactericidal effect of bismuth (III) benzohydroxamates 
against the microorganism. Due to this, iron mimicking processes 
the complexes are highly effective to more strongly kill the bacteria. 
Four complexes [Bi2(BHA)3], [Bi(H-BHA)3], [Bi(BHA)-(H-BHA)], 
and [Bi34O22(BHA)22(H-BHA)14(DMSO)6] were formed where BHA is 
benzohydroxamic acid structures were shown in Fig. 5 [101]. The 
bactericidal activity against three strains of H. pylori B128, 251, and 
26695 was tested by agar diffusion method, and MIC value ranges 
from 0.05 to 6.25 mg/mL. They also reported that benzohydroxamates 
were potentially more effective than the other complexes studied 
until now. Hence, further investigation of these complexes is 
required, and in same context novel bismuth (III) hydroxamates 
derived from N-methylfurohydroxamic acid (H-MFHA), N-benzoyl-N-
phenylhydroxamic acid (H-BPHA), salicylhydroxamic acid (H2-SHA), 
and acetohydroxamic acid (H2-AHA) were also synthesized [102]. Only 
acetohydroxamic acid is showed agility at low concentrations having 
MIC 6.25 µg/mL; 83.26 µM.
R=o-(OH)C6H5 R=o-(OH)C6H5 R=o-(OH)C6H5
R=C6H5 R=C6H5 R=C6H5
ORGANOBISMUTH COMPOUNDS WITH GASTROCYTOPROTECTIVE 
ACTIVITY
Andre Robert in 1979 was first to introduce the term “cytoprotection,” 
in a comprehensive sense it is related to protection against gastric 
mucosal injury by a mechanism other than reluctance or acclimatization 
of gastric acid. However, the surface cells are often not protected 
by these agents, so the term gastroprotection is suggested by Szabo 
and Szelenyi. Bismuth compounds are used as gastroprotective due 
to their local defensive, emollient, and antacid properties. Colloidal 
bismuth salt forms a protective coating against acid, pepsin, and bile 
by chelating proteins in the ulcer crater. A variety of experimental 
gastric mucosal lesions in the rat has been shown too prevented by this 
salt. Its cytoprotective effect has been attributed by increased luminal 
availability of epidermal growth factor, stimulation of prostaglandins, 
and stimulation of phospholipid-rich mucus [103].
178
Asian J Pharm Clin Res, Vol 12, Issue 5, 2019, 172-181
 Singh et al. 
Complex bismuth salt of citric acid is known as CBS. It is responsible 
for the appearance of bismuth oxychloride (BiOCl) and citric acid in 
the body, BiOCl is below par soluble, but bismuth ions have import 
physiological effects. It not only provides gastroprotective action but 
can also decrease the relapse rate. Prostaglandins also provide both 
antiulcer and ulcer protective activity and sucralfate is a standard drug 
used for experimental purposes. An acute gastric lesion induced by 
acidified aspirin and absolute ethanol in rats model was used to compare 
the effect of CBS with sucralfate and prostaglandins by Konturek et al. 
They found through a study that colloidal bismuth subcitrate is more 
potent than sucralfate and antiulcer action is dose-dependent. This 
study also shows that colloidal bismuth subcitrate is remarkable for the 
protection of gastric mucosa against acute necrosis induced by ethanol. 
CBS increase the biosynthesis of prostaglandins which stimulate the 
mucus alkaline secretion, tightening the mucosal barrier, increase in 
the mucosal refusal to accept acid, and mucosal cell renovation [104].
Tytgat reports a review on CBS allocating about the mechanism of 
action and its efficacy on DU and GU. He discussed that the defensive 
action of CBS is due to its plating film on the ulcer base, bolster of 
the mucus barriers against further acid attacks of the mucosa and 
stimulation of biosynthesis of endogenous prostaglandins with 
bicarbonate secretions. All these factors can speed up the ulcer healing 
and retard the relapses in both of the cases. He reports this remarkable 
phenomenon in ten different trails explaining two reasons that either 
CBS helps in eradication of H. pylori and results in improvements in 
gastroduodenal histology or stimulation of biosynthesis of endogenous 
prostaglandins may results in these relapses; further, he emphasizes 
that the reason first is more responsible for lower relapses [105]. 
Pharmacokinetic and pharmacodynamics studies of CBS were done by 
Wagstaff et al. A very low level of it is absorbed through GIT, most of 
the absorbed bismuth is found in kidney and some traces in the brain 
and it is excreted through urine and in some amount in feces. Healing 
of peptic ulcers in patients occurs over 4–8 weeks of treatment. After 
healing with CBS, the epithelial microvilli in the peptic ulcer scar are 
closer to normal like those in patients treated with cimetidine [106].
An indomethacin-induced injury in rats was used by Tanaka et al. 
to report the cytoprotective effect of BSS. An in vivo microscopic 
technique was used in which acid output, surface cell intracellular pH, 
gastric mucus gel thickness, and mucosal blood flow were measured 
simultaneously and using this technique they report that BSS improves 
pH during acid super fusion without affecting gel thickness, they cannot 
affect either mucosal blood flow or acid output [107]. BSS is a trivalent 
Fig. 5: Structure of bismuth complexes with hydroxamates
Fig. 3: Structure of bismuth tropolanato complexes, (a) in +3 and (b) in +5 oxidation state
a b
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salt of bismuth and salicylic acid, it reacts with hydrochloric acid in 
the stomach to form BiOCl and salicylic acid, it is also an insoluble 
salt so some amount is absorbed but remaining amount pass as such 
in duodenum and here reacts with bicarbonates and phosphates to 
form bismuth subcarbonate and bismuth phosphate, which results in 
darkening of stool. No other major side effects were noted except this 
darkening of the stool using BSS [108]. Tay et al. report that BSS can 
reduce peptic injury of the esophagus in rabbits. In this, in vivo study, 
they select perfused rabbit model to check the prevention of mucosal 
injury caused by pepsin through BSS and report a remarkable reduction 
in the pepsin induced interference of the mucosal barrier, as well as 
the difference in morphology by obstructing the proteolytic action of 
pepsin by BSS [109].
Stables et al. report RBC, which is a complex salt of ranitidine and 
bismuth citrate, various other salts were designed, but this one is stable 
enough. They report that along with the gastric acid anti-secretory 
effect of ranitidine these salts were protective against ethanol-induced 
gastric mucosal damage, inhibit pepsin activity, and suppress the 
activity of H. pylori and the related bacterium. Using the indomethacin-
induced antral damage model, they report that RBC is most potent in 
providing protective effects among RBC, bismuth citrate, ranitidine 
hydrochloride, and tripotassium dicitrato bismuthate.
Kotzampassi et al. reported RBC-related expansion of gastric mucosal 
microcirculation and stalwart mucus gel thickness which may 
contribute to the precautionary action; the examination was performed 
in fasted rats to assess the gastroprotective potential of ranitidine 
bismuth citrate. They report that there is an increase in blood flow of 
gastric mucosa as well as a significant improvement in gastric mucosal 
perfusion just an hour after a single oral dose of 25 mg/Kg body weight 
of RBC. Blood flow plays a very crucial role in the maintenance of 
gastric mucosal probity, since it regulates the transport of oxygen and 
nutritional substances and the fast removal of toxic metabolites and 
back-diffused hydrogen ions and other irritants [110].
FUTURE PERSPECTIVE
Various bismuth complexes such as CBS, BSS, RBC, and other novel 
bismuth complexes with amino-acids, aminoarenesulfonates, 
fluoroquinolones, sulfosalicylates, saccharinates, tropolanato, NSAIDs, 
thioxoketonates, benzohydroxamates, and thiosemicarbazones are 
mentioned above in the review which helps in the eradication of 
H. pylori as well as provide cytoprotective action through diverse 
mechanisms. These include disruption of multiple biological pathways 
through binding to various enzymes such as urease, ADH, fumarate 
reductase, fumarase, and protease and by binding to other intracellular 
proteins of H. pylori like heat shock protein-A and disruptions of nickel 
and iron homeostasis. Bismuth action is also exerted through binding to 
proteins such as metallothionein, transferrin, and lactoferrin.
The growing incidence of antimicrobial resistance has warned 
pharmaceutical scientists to implement new approaches for eradicating 
H. pylori infection. The therapeutic achievements of established drugs 
have been declined to significant levels. This emphasizes to explore 
some more potent bismuth complexes which specifically target some 
enzymatic actions or physiological processes in the organism which 
directly helps in the destruction of the bacterium.
H. pylori treatment may enter into an entirely new resistance era in 
the coming future which accounts for the development of some novel 
enzyme targeted approaches. In the current generation’s bismuth 
containing triple or quadruple therapy is an alternative line of 
treatment for H. pylori infection which was well established against 
multiple targets as mentioned above. Recently, some novel targets 
have been identified that warrants further investigation of bismuth-
containing compounds. Arginase has been established as one of the 
potential targets for a variety of synthesized derivatives and natural 
compounds. Arginase is a binuclear manganese metalloenzyme that 
converts L-arginine into ornithine and urea and it is also necessary 
for the growth of the infectious pathogen like H. pylori and suspected 
to be a cause of gastritis and peptic ulcers. It was reported by Pudlo 
et al. that alpha amino-acids such as glycine, alanine, valine, leucine, 
and isoleucine are weak inhibitors of arginase. Ornithine, lysine, 
L-cysteine, and L-glutamic acid are also inhibitors of arginase [111]. 
Amino acid derivatives such as hydroxyl derivative of L-arginine and 
alpha-difluromethylornithine an ornithine derivative are also reported 
as inhibitors of arginase. In silico approaches to identify the plausible 
binding sites of arginase followed by rational drug designing strategies 
to construct novel alpha amino-acid complexes of bismuth may be 
tested to explore the arginase mediated mechanism to target H. pylori.
Investigations on bacterial physiology on molecular levels lead to 
the discovery of some new mechanistic approaches like inhibition of 
shikimate pathway which is responsible for the production of some vital 
amino acids. Several enzymes involved at different levels of shikimate 
pathway have been investigated and subsequently targeted. Some other 
crucial targets have been identified by computational approaches which 
include the discovery of the succinylase pathway which was utilized by 
H. pylori to produce lysine [112]. Exploration of these pathways with 
bismuth containing compounds may provide a valuable understanding 
of novel mechanisms in the treatment of peptic ulcers.
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